Despite advances in imaging with [68Ga]Ga-PSMA-11 or [18F]F-DCFPyl for PCa detection/staging [3,4,5,6], and encouraging results achieved with novel radiotherapeutic agents, such as the bone-targeting radionuclide radium-223 [7] or [177Lu]Lu-PSMA-617 [8], eventually all patients with advanced disease will progress to metastatic castration-resistant prostate cancer (mCRPC). This evidence concerns the gene FOLH1 and posterior cortical atrophy.